Reuters reported that research suggests SGLT-2 inhibitors, “a newer class of type 2 diabetes” medications, “significantly cut the risk of death and hospitalization for heart failure compared with other medicines for the disease.” The findings were presented at the American College of Cardiology meeting.
No comments:
Post a Comment